The Pharmaceutical Market: France

Date: January 31, 2013
Pages: 107
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PAE70BBC09BEN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: France
OVERVIEW OF THE PHARMACEUTICAL MARKET IN FRANCE

France's high public debt-to-GDP ratio will necessitate more aggressive fiscal tightening by the state. This includestargeting the pharmaceuticals and healthcare sector, whichcurrentlyreceivesa large proportion of public funds.

Headline Expenditure Projections

Pharmaceuticals: EUR35.01bn (US$48.66bn) in 2011 to EUR34.17bn (US$43.39bn) in 2012.
-2.4% in local currency terms and -10.8% in US dollar terms. Local currency forecast broadly unchanged from Q3 12.

Healthcare: EUR234.30bn (US$325.68bn) in 2011 to EUR239.29bn (US$303.89bn) in 2012; +2.1% in local currency terms and -6.7% in US dollar terms. Local currency forecast slightly lower f rom Q312 on account of worsening macroeconomic environment .

Medical devices: EUR10.72bn (US$14.89bn) in 2011 to EUR11.07bn (US$14.06bn) in 2012; +3.3% in local currency terms and -5.61% in US dollar terms. Local currency forecast broadly unchanged from Q312.
Risk/Reward Ratings: France remains ranked fourth out of the 10 markets in BMI's Western Europe Pharmaceutical

Risk/Reward Ratings (RRR) matrix for Q113, with an unchanged composite score, at 67.9 out of the maximum 100 points. The country's reward profile remains considerably less attractive than its risk score, reinforcing our view of the country's potential due to a stronger emphasis on the regulatory environment, which we regard as a major factor affecting the business environment for drugmakers, rather than on the basis of real opportunities for higher per-capita drug consumption.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    France Pharmaceuticals And Healthcare Industry SWOT
    France Political SWOT
    France Economic SWOT
    France Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

    Table: Western Europe Pharmaceuticals And Healthcare Risk/Reward Ratings, Q113
    Rewards
    Risks

MARKET SUMMARY

REGULATORY REGIME

    Intellectual Property Developments
    Pricing And Reimbursement Issues
    Table: France Reimbursement Categories
    Measures Targetting Pharmaceutical Expenditure
    Evaluation Of Treatments
    Pricing And Reimbursement Developments
    'European Price' Developments
    OTC Market Developments

INDUSTRY TRENDS AND DEVELOPMENTS

    Epidemiology
    Prescribing Habits
    Healthcare Financing
    Public Hospitals
    Ambulatory Care
    Services
    Table: Hospital Activity, 2005-2009
    Table: Hospital Activity in Short-Stay Units, 2009
    Table: Diagnostic & Therapeutic Procedures Performed in Public & Private Hospitals, 2009
    Ambulatory Activity
    Table: Regional Ranking of Projected Physicians, 2017
    Table: Projected Physicians, 2012-2017
    Latest Figures
    Table: Medical Personnel, 2005-2010
  Encouragement of Generic Drug Use
    Research And Development
    Biotechnology Sector
    Clinical Trials
    Medical Devices

INDUSTRY FORECAST SCENARIO

  Overall Market Forecast
      Table: Pharmaceutical Sales Indicators 2008-2016
  Healthcare Market Forecast
      Table: Healthcare Expenditure Indicators 2008-2016
      Table: Healthcare Governmental Indicators 2008-2016
      Table: Healthcare Private Indicators 2008-2016
  Key Growth Factors – Macroeconomic
      Table: Economic Activity
  Prescription Drug Market Forecast
      Table: Prescription Drug Sales Indicators 2008-2016
  Patented Product Market Forecast
      Table: Patented Drug Market Indicators 2008-2016
  Generic Drug Market Forecast
      Table: Generic Drug Sales Indicators 2008-2016
  OTC Medicine Market Forecast
      Table: OTC Medicine Sales Indicators 2008-2016
  Pharmaceutical Trade Forecast
      Table: Exports and Imports Indicators 2008-2016
  Medical Device Market Forecast
      Table: Medical Devices Sales Indicators 2008-2016
  Other Healthcare Data
  Key Risks To BMI's Forecasts

COMPETITIVE LANDSCAPE

      Pharmaceutical Industry
      Table: French Pharmaceutical Companies According To Market Capitalisation
      Company Developments
      Foreign Companies
      Wholesale Sector
      Pharmacy Sector

COMPANY MONITOR

  Local Companies
      Sanofi
      Servier
      Ipsen
  Multinational Companies
      Pfizer
      GlaxoSmithKline
      Novartis
      Merck & Co

DEMOGRAPHIC OUTLOOK

      Table: France's Population By Age Group, 1990-2020 ('000)
      Table: France's Population By Age Group, 1990-2020 (% of total)
      Table: France's Key Population Ratios, 1990-2020
      Table: France's Rural And Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

  How We Generate Our Pharmaceutical Industry Forecasts
    Pharmaceutical Risk/Reward Ratings Methodology
    Ratings Overview
    Table: Pharmaceutical Risk/Reward Indicators
    Weighting
    Table: Weighting Of Components
    Sources
Skip to top


The Pharmaceutical Market: Malaysia US$ 1,295.00 Jan, 2013 · 113 pages
The Pharmaceutical Market: Philippines US$ 1,295.00 Jan, 2013 · 103 pages
The Pharmaceutical Market: Poland US$ 1,295.00 Jan, 2013 · 102 pages
The Pharmaceutical Market: Portugal US$ 1,295.00 Jan, 2013 · 91 pages
The Pharmaceutical Market: Romania US$ 1,295.00 Jan, 2013 · 93 pages

Ask Your Question

The Pharmaceutical Market: France
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: